



Repligen Corporation
41 Seyon Street
Building #1, Suite 100
Waltham, Massachusetts 02453
Telephone: 781-250-0111
Telefax: 781-250-0115

FOR IMMEDIATE RELEASE

CONTACT:

Laura L. Whitehouse
VP, Market Development
(781) 419-1812

Repligen Announces Initiation of RG1068 Pilot Study to Improve Identification and Characterization of Pancreatic Cancer

WALTHAM, MA – July 21, 2011 – Repligen Corporation (NASDAQ: RGEN) today announced that the first patient has been enrolled in a pilot study to evaluate the ability of RG1068 to improve detection and characterization of pancreatic cancer in combination with contrast-enhanced magnetic resonance imaging (MRI) and computed tomography (CT). In addition, this study will evaluate which imaging technique is optimal for pancreatic tumor detection, staging and evaluation for surgery. This study will enroll up to 40 patients with a known or suspected pancreatic mass and the presence of a tumor will be confirmed by either surgery or biopsy. Early detection of pancreatic cancer will increase the identification of patients who are candidates for surgery and may improve patient outcomes. This is an investigator-sponsored study lead by Pablo R. Ros, M.D., Chairman, Department of Radiology, University Hospitals Case Medical Center in Cleveland Ohio, affiliated with Case Western University.

“Accurate and early tumor detection and staging are fundamental for treating patients with pancreatic cancer,” stated Pablo R. Ros, M.D., the principal investigator of the study. “We are excited about this prospective study we have started since if successful, RG1068 has the potential to improve our ability to detect and correctly stage pancreatic tumors by CT and MRI scans and may lead to improved patient outcomes.”

RG1068, a synthetic version of the hormone secretin, is known to both stimulate the secretion of pancreatic fluid into the pancreatic ducts and to increase blood flow to the tissues of the pancreas. Pancreatic tumors have minimal blood flow and the addition of RG1068 to standard contrast-enhanced imaging techniques which are currently ineffective in resolving early disease may enable the tumor to become more visible. In general, tumors that are less than 3 centimeters are amenable to surgical removal, the only viable form of treatment. Optimal triage and planning for surgery requires the detection of the tumor, evaluation of its size, and relationship to major blood vessels, lymph nodes and presence of metastases.

“Patient enrollment in this study is an important milestone for RG1068 as there is a clear medical need for improved detection and characterization of pancreatic cancer,” stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. “If successful, this would be a significant market opportunity for RG1068.”

RG1068 has previously been shown in Phase 3 clinical trials to improve detection of pancreatic duct abnormalities in combination with MRI in patients with pancreatitis. Identification of pancreatic duct abnormalities is important in the identification of the cause of a patient’s symptoms and improves the physician’s ability to confidently plan the next step in treatment. RG1068 has been granted Fast Track

Repligen Announces Initiation of RG1068 Pilot Study to Improve Identification and Characterization of Pancreatic Cancer, July 21, 2011

Designation and we intend to request that the FDA grant our application priority review when we file our New Drug Application in the U.S. later this year. We plan to build a lean commercial infrastructure to sell RG1068 in the U.S. directly and to establish one or more commercial partnerships outside of the U.S. There are approximately 300,000 MRI procedures conducted in patients with pancreatitis in the U.S. and Europe each year that could directly benefit from the addition of RG1068.

About Pancreatic Adenocarcinoma

Pancreatic cancer remains the fourth leading cause of cancer-related death in the U. S. The annual incidence of the disease approximates its annual mortality, largely due to the advanced stage at which most patients present. Accurate tumor detection and staging are critical to managing patients with pancreatic adenocarcinoma. The lack of accurate and cost-effective screening and detection techniques, technical difficulty in obtaining tissue samples when a mass is identified, and rapid progression of the disease, all contribute to the advanced presentation and high mortality rate. There are approximately 250,000 people worldwide diagnosed with pancreatic cancer each year.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on building an integrated company by developing and marketing innovative drugs that deliver the benefits of protein therapies in the fields of neurology and gastroenterology. We have a core competency in the development and manufacturing of biologics products, which is the basis for our bioprocessing business and we have out-licensed certain biologics intellectual property, which provide ongoing sources of revenue. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested at www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property protection, product development, manufacturing plans and performance, projected changes in the size of our markets, our market share and product sales and other statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of our clinical trials; our ability to develop and commercialize products; our ability to obtain required regulatory approvals; the success of current and future collaborative relationships; the market acceptance of our products; our ability to compete with larger, better financed pharmaceutical and biotechnology companies; new approaches to the treatment of our targeted diseases; our expectation of incurring continued losses; our uncertainty of product revenues and profits; our ability to generate future revenues; our ability to raise additional capital to continue our drug development programs; our compliance with all Food and Drug Administration regulations; our ability to obtain, maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales and manufacturing capabilities; our dependence on third-party manufacturers and value added resellers; our ability to hire and retain skilled personnel; our volatile stock price; and other risks detailed in Repligen's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management's current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.